Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Merck & Company (MRK – Research Report), with a price ...

Since taking over in late 2023, Alex Chriss, PayPal chief executive, has focused on high-margin products and touted ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

Hopes were high for a rebound in capital-markets activity this year A few notable Health Care deals along with M&A in the ...

4425.80. On previous day, the Pfizer Share Price (NSE) closed at Rs. 4562.85, featuring among the most traded securities on the National Stock Exchange.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...